Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus low-dose steroids for idiopathic membranous nephropathy
ChiCTR2000040799Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in idiopathic membranous glomerulonephritis (IMG), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Complete remission of nephrotic syndrome. Started May 2020; status: recruiting.
02
Drugs
rituximab
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on ChiCTR2000040799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040799.